# EDGAR Filing Document

**Accession Number:** 0001730430
**File Stem:** 0001415889-23-005233
**Filing Date:** 2023-3
**Character Count:** 6777
**Document Hash:** 1aa49c94512fc1375f2126bf8b540c64
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-23-005233.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001415889-23-005233

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230316

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Patel Sanj K
- **CENTRAL INDEX KEY:** 0001532218

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38492
- **FILM NUMBER:** 23747136

**MAIL ADDRESS:**
- **STREET 1:** C/O KINIKSA PHARMACEUTICALS, LTD.
- **STREET 2:** CLARENDON HOUSE, 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kiniksa Pharmaceuticals, Ltd.
- **CENTRAL INDEX KEY:** 0001730430
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11
- **BUSINESS PHONE:** 7814399100

**MAIL ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Patel Sanj K<br><sub>(Last) (First) (Middle)</sub><br>C/O KINIKSA PHARMACEUTICALS, LTD.<br>CLARENDON HOUSE 2 CHURCH STREET<br><sub>(Street)</sub><br>HAMILTON, D0 HM 11<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHAIRMAN & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Kiniksa Pharmaceuticals, Ltd. [ KNSA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Share | 2023-03-16 |  | M |  | 6569 | A | <sup>(1)</sup> | 28965 | D |  |
| Class A Common Share | 2023-03-16 |  | F |  | 1929 | D | $11.46 | 27036 | D |  |
| Class A Common Share | 2023-03-20 |  | M |  | 12002 | A | <sup>(1)</sup> | 39038 | D |  |
| Class A Common Share | 2023-03-20 |  | F |  | 3523 | D | $11.12 | 35515 | D |  |
| Class A Common Share |  |  |  |  |  |  |  | 83336 | I | Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 |
| Class A Common Share |  |  |  |  |  |  |  | 109795 | I | Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Share Unit | <sup>(1)</sup> | 2023-03-16 |  | M |  |  | 6569 | <sup>(2)</sup> | <sup>(2)</sup> | Class A Common Share | 6569 | $0 | 13138 | D |  |
| Restricted Share Unit | <sup>(1)</sup> | 2023-03-20 |  | M |  |  | 12002 | <sup>(3)</sup> | <sup>(3)</sup> | Class A Common Share | 12002 | $0 | 0 | D |  |

---

### Footnotes:

(1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

(2) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

(3) The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.

**Signature:** /s/ Madelyn Zeylikman, Attorney-in-Fact  
**Date:** 2023-03-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**